Skip to content
Home » Pharmaceutical

Pharmaceutical

scientist in laboratory

mRNA vaccine for pancreatic cancer — excellent long-term results

Recent long-term clinical trial data reveals the personalized mRNA vaccine, cevumeran, elicits a lasting immune response in pancreatic cancer patients, significantly improving recurrence-free survival. The phase 2 trial explores cevumeran’s combined efficacy with chemotherapy, as this approach shows potential to revolutionize treatment for this hard-to-treat cancer, underscoring mRNA vaccines’ role in advancing medical treatments.

close up photo of a wooden gavel

Judge in Gardasil lawsuit throws out most claims

Dorit Rubinstein Reiss, a law professor and vaccination policy expert, discusses a federal judge’s recent decision in the Gardasil lawsuit, which barred several claims against Merck as preempted by the National Childhood Vaccine Injury Act but permitted discovery to proceed on claims involving failure to warn the plaintiffs’ doctors and fraudulent concealment. This pivotal ruling reduced the scope of the plaintiffs’ cases, originally marked by broad allegations, to more specific claims of deficient warnings to healthcare providers and concealed risks, despite substantial evidence against the alleged harms of the HPV vaccine.

doctors and nurses in a hospital

New mRNA vaccine for pancreatic cancer enters phase 2 trials

A new personalized mRNA vaccine for pancreatic cancer, cevumeran, has shown promise in a phase 1 trial and is advancing to a larger phase 2 trial. It works by inducing an immune response against specific antigens in each patient’s tumor, offering hope for a disease with typically poor prognosis. Developed by BioNTech, cevumeran complements standard treatments like surgery and chemotherapy, potentially increasing overall success rates.

silhouette photo of man doing heart sign during golden hour

NFL star Travis Kelce posts a heart photo — anti-vaxxers go crazy

NFL star Travis Kelce, tagged “Mr. Pfizer,” came under anti-vaccine fire for an Instagram post where he made a heart shape with his hands, sparking baseless claims of vaccine dangers. Contrary to myths, COVID-19 vaccines have a much lower myocarditis risk than the virus itself, and other heart issues aren’t linked to the vaccine. The American Heart Association endorses vaccines, especially for those with heart conditions. Kelce’s gesture likely celebrated the Super Bowl win or expressed love, not a vaccine warning.

pregnancy COVID-19 vaccine

COVID-19 vaccine during pregnancy – the CDC now recommends it

The CDC endorses the COVID-19 vaccine for pregnant individuals based on a study showing no significant safety concerns. Research involving 35,691 pregnant participants found typical vaccination symptoms and no evidence of increased risk for adverse pregnancy outcomes. The findings suggest the vaccine’s efficacy and safety during pregnancy, reinforcing its importance for maternal and fetal health.

FDA unproven drug

Pressure on the FDA to approve an unproven drug

In a pressure campaign to sway the FDA, advocates seek approval for an unproven drug to treat a rare genetic disorder. Despite public outcry, the FDA refused to greenlight the drug after it failed to demonstrate efficacy in a small-scale trial. It’s crucial to balance emotion with evidence in evaluating drug effectiveness. The FDA should not be swayed by public pressure to approve potentially unsafe drugs.

mumps vaccine effectiveness

Mumps vaccine effectiveness — the facts

Professor Dorit Rubinstein Reiss discussed a whistleblower lawsuit against Merck regarding its mumps vaccine. Though the case was dismissed, concerns remain about the vaccine’s effectiveness. Regardless, scientific evidence supports the MMR vaccine’s safety and effectiveness against mumps, a disease that can have serious complications. Waning immunity and incomplete vaccination may be contributing to recent mumps outbreaks.

Merck mumps vaccine lawsuit

District Court dismisses 2010 Merck mumps vaccine lawsuit

In July 2023, a False Claims Act lawsuit against Merck, alleging fraud related to the mumps vaccine, was dismissed due to lack of material evidence. The court found that the government’s decision to contract with Merck was based on its own data about effectiveness, rendering any misrepresentations by Merck immaterial. The lawsuit has been appealed to the Third Circuit.